LETTER
Stereocontrol in the Synthesis of Y[CH(RF)NH]Gly Peptides
961
Pr2O, 7:3) and 10b (Rf = 0.41, n-hexane–i-Pr2O, 7:3), in a ratio of
7.5:1.0.
Ph
O
RF
RF
i
H
O2N
N
N
COOt-Bu ii
PG
N
N
COOt-Bu
H
H
H
Typical Procedure for the Synthesis of the Fluorinated Tripep-
tide Mimics 11
9h,p
11h: RF = CF2H, PG = Boc, 86%
11p: RF = CF2Cl, PG = Cbz, 79%
A solution of 9p (0.11 mmol, 33 mg) and 1 N HCl (0.11 mmol, 110
mL), in MeOH (2 mL) and in the presence of a catalytic amount of
Pd(OH)2/C, was stirred at r.t. for 5 h under hydrogen atmosphere.
Then, the mixture was filtered on a Celite pad, the solvent removed
in vacuo. The crude was dissolved in 1 mL of dry DMF and Cbz-L-
Phe-OH, (0.11 mmol, 32.9 mg) followed by sym-collidine (0.22
mmol, 30 mL), HOAt (0.11 mmol, 14.9 mg), HATU (0.11 mmol,
41.8 mg) were added at r.t. The mixture was stirred overnight,
quenched with 1 N HCl, and extracted with Et2O. The organic layer
was washed once with H2O and then dried on Na2SO4. The solvent
was removed in vacuo, and the crude purified by flash chromatog-
raphy (hexane–EtOAc, 70:30) affording 50.6 mg of 11p (79%).
Ph
RF
H
RF
i
O2N
N
ii
N
H
COOMe
PG
N
N
COOMe
H
H
O
9j,r
11j: RF = CF2Me, PG = Boc, 88%
11r: RF = CF2Br, PG = Boc, 93%
Ph
Ph
Ph
i
RF
RF
H
O2N
N
ii
N
H
COOt-Bu
PG
N
N
COOt-Bu
Compound 11p
H
H
Rf = 0.35 (hexane–EtOAc, 8:2); [a]D20 +9 (c 1.1, CHCl3). 1H NMR
(400 MHz, CDCl3): d = 7.40–7.10 (m, 10 H), 5.52 (br s, 1 H), 5.11
(d, J = 12.3 Hz, 1 H), 5.00 (d, J = 12.3 Hz, 1 H), 4.56 (br s, 1 H),
3.49 (dt, J = 13.6, 4.3 Hz, 1 H), 3.39 (m, 1 H), 3.25 (d, J = 3.7 Hz,
1 H), 3.19 (dd, J = 13.7, 5.9 Hz, 1 H), 3.06 (br m, 1 H), 2.94 (br m,
1 H), 2.03 (m, 1 H), 1.55 (br s, 1 H), 1.46 (s, 9 H), 0.99 (d, J = 6.8
Hz, 3 H), 0.83 (d, J = 6.8 Hz, 3 H). 19F NMR (470.6 MHz, CDCl3):
d = –60.2 (dd, J = 177.3, 6.0 Hz, 1 F), –60.8 (dd, J = 177.3, 8.6 Hz,
1 F). 13C NMR (100.6 MHz, CDCl3): d = 175.86, 172.01, 137.08,
136.76, 130.90 (t, J = 296.7 Hz), 129.75, 129.59, 129.19, 128.84 (d,
J = 4.2 Hz), 128.45 (d, J = 8.5 Hz), 127.22, 82.63, 67.27, 66.45,
64.11 (t, J = 24.5 Hz), 56.66, 40.10, 40.06, 31.86, 28.48, 19.83,
17.59. ESI-MS: m/z (%) = 582.3 (15) [M+ + H], 604.3 (100) [M+ +
Na], 620.2 (23) [M+ + K].
O
9w
11w: RF = CF2CF3, PG = Cbz, 94%
Scheme 2 Elaboration of the aza-Michael adducts 9 into the targets
peptidomimetics 11. Reagents and conditions: i) H2, Pd(OH)2/C, aq
HCl–MeOH; ii) PG-LPhe-OH, HATU and HOAt, TMP, DMF.
steric factors in the control of the diastereoselectivity of
aza-Michael reactions.
Elaboration of the major adducts 9 into the target
Y[CH(RF)NH]Gly peptides 11 (Scheme 2) was addressed
next. Reduction of the nitro group of 9 was accomplished
by using Parlman’s catalyst in the presence of aqueous 1
N HCl to trap the free amino function as hydrochloride
salt. Coupling with Boc(Cbz)-L-Phe-OH using HOBt and
EDC afforded Boc(Cbz)-L-Phe-Y[CH(RF)NH]Gly-L-
Val-Ot-Bu (11), in very good yields.
Acknowledgment
We thank MIUR (PRIN 2004 project ‘Polipeptidi Bioattivi e Nano-
strutturati’), Politecnico di Milano, and C.N.R. for economic sup-
port. We thank Dr. M. Molteni for preliminary experiments.
In summary, a new class of peptidomimetics having di-
verse [CH(RF)NH] functions as surrogates of the scissile
peptide bond, namely Y[CH(RF)NH]Gly peptides are
now available. The aza-Michael addition of a-amino acid
esters 8 to fluoroalkyl nitroethenes 2–7 represents the key
synthetic step. The diastereoselectivity of this reaction,
which was already known to be dependent on the base and
its stoichiometry, solvent, temperature, and R side chain
of 8, resulted to be strongly influenced also by the elec-
tronegativity, rather than the steric bulk, of the fluorinated
RF group in b-position to the nitroethene acceptors. The
synthesis of more complex Y[CH(RF)NH] peptides and
the study of their conformation in solution, as well as cal-
culations and mechanistic studies, are currently being ad-
dressed.
References and Notes
(1) (a) Olson, G. L.; Bolin, D. R.; Bonner, M. P.; Bös, M.; Cook,
C. M.; Fry, D. C.; Graves, B. J.; Hatada, M.; Hill, D. E.;
Kahn, M.; Madison, V. S.; Rusiecki, V. K.; Sarabu, R.;
Sepinwall, J.; Vincent, G. P.; Voss, M. E. J. Med. Chem.
1993, 36, 3039. (b) Gante, J. Angew. Chem., Int. Ed. Engl.
1994, 33, 1699. (c) Leung, D.; Abbenante, G.; Fairlie, D. P.
J. Med. Chem. 2000, 43, 305.
(2) Fauchère, J.-L.; Thurieau, C. Adv. Drug Res. 1992, 23, 127.
(3) Spatola, A. F. In Chemistry and Biochemistry of Amino
Acids, Peptides and Proteins, Vol. 7; Weinstein, B., Ed.;
Marcel Dekker: New York, 1983, 267–357.
(4) (a) Morley, J. S.; Hennessey, T. D.; Payne, J. W. Biochem.
Soc. Trans. 1983, 11, 798. (b) Smith, A. B. III; Hirschmann,
R.; Pasternak, A.; Guzman, M. C.; Yokoyama, A.;
Sprengeler, P. A.; Darke, P. L.; Emini, E. A.; Schleif, W. A.
J. Am. Chem. Soc. 1995, 117, 11113.
Typical Procedure for the Michael Addition
To a stirred solution of 2 (0.76 mmol, 107 mg) and 8b (0.51 mmol,
92 mg) in toluene (7 mL) at r.t., DIPEA was added (0.56 mmol, 73
mL). After 30 min at r.t., the solvent was removed in vacuo, the
crude residue was dissolved in EtOAc, and washed once with 1 N
HCl. The organic layer was dried over anhydrous Na2SO4. The sol-
vent was removed in vacuo, and the crude was purified by flash
chromatography (hexane–diisopropyl ether, 9:1) affording 110 mg
(75%) of the two pure diastereoisomers 9b (Rf = 0.31, n-hexane–i-
(5) For a review on the trifluoethylamine unit, see: Sani, M.;
Volonterio, A.; Zanda, M. ChemMedChem 2007, 2, 1693.
(6) Volonterio, A.; Bellosta, S.; Bravin, F.; Bellucci, M. C.;
Bruché, L.; Colombo, G.; Malpezzi, L.; Mazzini, S.; Meille,
S. V.; Meli, M.; Ramirez de Arellano, C.; Zanda, M. Chem.
Eur. J. 2003, 9, 4510; and references cited therein.
(7) Molteni, M.; Volonterio, A.; Zanda, M. Org. Lett. 2003, 5,
3887.
Synlett 2008, No. 7, 958–962 © Thieme Stuttgart · New York